演題詳細

ポスター / Poster

ポスター 26 (Poster 26) :B細胞性リンパ腫:Chemotherapy

print

日程
2013年10月11日(金)
時間
16:50 - 17:50
会場
ポスター会場 / Poster (ロイトン札幌 3F ロイトンホールABCD)
座長・司会
塚本 憲史 (Norifumi Tsukamoto):1
1:群馬大学医学部附属病院 腫瘍センター
 
前へ戻る

Peripheral blood T cell subsets during the chemotherapy for malignant lymphoma

演題番号 : PS-1-193

大宮 千春 (Chiharu Omiya):1、小磯 博美 (Hiromi Koiso):2、神谷 明 (Akira Kamiya):1、渡部 悟 (Satoru Watanabe):1、齋藤 貴之 (Takayuki Saitoh):1、塚本 憲史 (Norifumi Tsukamoto):2、横濱 章彦 (Akihiko Yokohama):3、三井 健揮 (Takeki Mitsui):4、半田 寛 (Hiroshi Handa):4、村上 博和 (Hirokazu Murakami):1

1:Gunma Graduate School of Health Sciences、2:Oncology Center, Gunma University Hospital, Maebashi, Japan.、3:Division of Blood Trasfusion Service, Gunma University Hospital, Maebashi, Japan.、4:Department of Medicine and Clinical Sciences, Gunma University Graduate School of Medicine, Maebashi, Japan.

 

Objective: Malignant lymphoma patients were treated with a CHOP-based chemotherapy containing rituximab. We observed the changes of peripheral blood T cell subsets before and after R-CHOP therapy.Patients and methods: Eleven malignant lymphoma patients were treated with 6 or 8 cycles of R-CHOP regimen. In order to clarify the immunological changes induced by this regimen, we analyzed the number and rations of the following cells in peripheral blood : CD3 + T cells, CD4+ T cells, CD8+ T cells, T helper 1 cells (Th1), T helper 2 cells (Th2), CD4+CD25+ T cells, Foxp3+ regulatory T cells (Tregs), CD4/CD8 ratio, Th1/Th2 ratio and CD8/Treg ratio at each course of therapy and after 3 and 6 months after the therapy.Results: The numbers of CD3+ and CD8+ T cells gradually decreased during the therapy, and showed the lowest values at the end of therapy, but recovered after the therapy. CD4+ T cells and CD4/CD8 ratio quickly decreased after the first course, and not recovered after the therapy. CD4+CD25+ T cells and Tregs decreased after 3 courses, and gradually recovered after the therapy. Th1 and Th2 cells quickly deceased after the first course, and not recovered after the therapy. CD8/Treg ratio increases at 2-fold of pre-treatment value after the therapy.Conclusion: Our data suggested that R-CHOP therapy affected not only B cells but also helper T cells, and perpetuated humoral immune-deficiency. CD8/Treg ratio, which was reported as a benign prognostic marker in ovarian cancer and myelodysplastic syndrome, increased after the therapy.

前へ戻る